Fig. 3: SRT2104 treatment reduces fibrosis and promotes regeneration in mdx mice.

A Sirius red staining labeling fibrotic tissue in DP muscle of WT, mdx vehicle, and mdx upon SRT2104 treatment (scale bar = 100 μm). Quantification of fibrosis is provided (right panel) (WT n = 3; mdx veh n = 12; mdx SRT2104 n = 7). B RT-qPCR analysis of fibrotic genes COL1A1, CTGF, α-SMA, and TGF-β in DP of vehicle- and SRT2104-treated mdx mice (mdx veh n ≥ 10; mdx SRT2104 n = 9). C, D Representative immunostaining of embryonic myosin heavy chain (MyHC3-Emb) to identify regenerating fibers and MYOZ1 to assess myofibers maturity (scale bars = 100 μm). Quantification of MyHC-Emb regeneration foci relative to mdx vehicle (WT n = 3; mdx veh n = 10; mdx SRT2104 n = 8) and MYOZ1 staining on total sections area (WT n = 3; mdx veh n = 6; mdx SRT2104 n = 3) are provided. A–D * versus WT mice (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001); + versus vehicle-treated mdx mice (+ P < 0.05, +++ P < 0.001.) B * versus vehicle-treated mdx mice (** P < 0.01, *** P < 0.001, **** P < 0.0001). Values are expressed as mean ± SEM.